Neoadjuvant DAN-222 plus niraparib in high-risk HER2-negative breast cancer: Results from the I-SPY 2 adaptive platform trial.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Kay T. Yeung, Claudine Isaacs, Marissa Howard-Mcnatt, Christina Yau, Jo Chien, Anne M. Wallace, Judy Caroline Boughey, Hyo S. Han, Virginia F. Borges, Carla Isadora Falkson, Douglas Yee, Coral Omene, Rita Nanda, Andrew Chapple, Jane Perlmutter, Paula R. Pohlmann, Alexander D. Borowsky, W. Fraser Symmans, Laura van't Veer, Laura Esserman
Institutions: Moores Cancer Center, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Wake Forest University, University of California, San Francisco, Mayo Clinic, Moffitt Cancer Center, University of Colorado Cancer Center, University of Rochester Medicine, University of Minnesota, Masonic Cancer Center, Rutgers Cancer Institute, University of Chicago, Quantum Leap Healthcare Collaborative, The University of Texas MD Anderson Cancer Center, Alliance for Clinical Trials in Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162555081
Cites:
Cited by:
Related to: